CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-02, Vol.13 (4), p.596 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 596 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Richardson, Jennifer R Schöllhorn, Anna Gouttefangeas, Cécile Schuhmacher, Juliane |
| description | Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer. |
| doi_str_mv | 10.3390/cancers13040596 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7913359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2487224245</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-2a4a2e9c1092897caac40c1337d501bfea11d8c0070b90ebdc3113e10998f7653</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMottSu3UnAjSBj85rJxIUgUx-Fipu6DplMpp06j5rMCP33pg-lNpuEe7-cew8HgEuM7igVaKRVrY11mCKGQhGdgD5BnARRJNjpwbsHhs4tkT-UYh7xc9CjNGQRiWkfjJMxu4UzmJiydPfwrSvbolXus6jnuxosatguDBx37Ro2OUy2Q-Gkqrq68Q2rVusLcJar0pnh_h6Aj-enWfIaTN9fJsnjNNCM4DYgiilihMZIkFhwrZRmSGNKeRYinOZGYZzFGiGOUoFMmmmKMTUeF3HOo5AOwMNOd9Wllcm0qVurSrmyRaXsWjaqkP87dbGQ8-ZbcuGnhMIL3OwFbPPVGdfKqnDa21S1aTonCYs5DuNIEI9eH6HLprO1t7elCGGEbTYa7ShtG-esyf-WwUhuQpJHIfkfV4ce_vjfSOgPHeyMrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487224245</pqid></control><display><type>article</type><title>CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Richardson, Jennifer R ; Schöllhorn, Anna ; Gouttefangeas, Cécile ; Schuhmacher, Juliane</creator><creatorcontrib>Richardson, Jennifer R ; Schöllhorn, Anna ; Gouttefangeas, Cécile ; Schuhmacher, Juliane</creatorcontrib><description>Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13040596</identifier><identifier>PMID: 33546283</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Antitumor activity ; Cancer ; Cancer immunotherapy ; CD4 antigen ; CD8 antigen ; Cell activation ; Chemokines ; Cytokines ; Cytotoxicity ; Growth factors ; Immunotherapy ; Ligands ; Lymphocytes ; Lymphocytes T ; Macrophages ; Major histocompatibility complex ; Pathogens ; Peptides ; Review ; T cell receptors ; Tumor cells ; Tumor necrosis factor-TNF</subject><ispartof>Cancers, 2021-02, Vol.13 (4), p.596</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-2a4a2e9c1092897caac40c1337d501bfea11d8c0070b90ebdc3113e10998f7653</citedby><cites>FETCH-LOGICAL-c421t-2a4a2e9c1092897caac40c1337d501bfea11d8c0070b90ebdc3113e10998f7653</cites><orcidid>0000-0003-0553-3474 ; 0000-0002-6410-2378 ; 0000-0001-7928-7312 ; 0000-0001-5312-2755</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913359/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913359/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33546283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Richardson, Jennifer R</creatorcontrib><creatorcontrib>Schöllhorn, Anna</creatorcontrib><creatorcontrib>Gouttefangeas, Cécile</creatorcontrib><creatorcontrib>Schuhmacher, Juliane</creatorcontrib><title>CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.</description><subject>Antigens</subject><subject>Antitumor activity</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Cell activation</subject><subject>Chemokines</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Growth factors</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Major histocompatibility complex</subject><subject>Pathogens</subject><subject>Peptides</subject><subject>Review</subject><subject>T cell receptors</subject><subject>Tumor cells</subject><subject>Tumor necrosis factor-TNF</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtLAzEUhYMottSu3UnAjSBj85rJxIUgUx-Fipu6DplMpp06j5rMCP33pg-lNpuEe7-cew8HgEuM7igVaKRVrY11mCKGQhGdgD5BnARRJNjpwbsHhs4tkT-UYh7xc9CjNGQRiWkfjJMxu4UzmJiydPfwrSvbolXus6jnuxosatguDBx37Ro2OUy2Q-Gkqrq68Q2rVusLcJar0pnh_h6Aj-enWfIaTN9fJsnjNNCM4DYgiilihMZIkFhwrZRmSGNKeRYinOZGYZzFGiGOUoFMmmmKMTUeF3HOo5AOwMNOd9Wllcm0qVurSrmyRaXsWjaqkP87dbGQ8-ZbcuGnhMIL3OwFbPPVGdfKqnDa21S1aTonCYs5DuNIEI9eH6HLprO1t7elCGGEbTYa7ShtG-esyf-WwUhuQpJHIfkfV4ce_vjfSOgPHeyMrw</recordid><startdate>20210203</startdate><enddate>20210203</enddate><creator>Richardson, Jennifer R</creator><creator>Schöllhorn, Anna</creator><creator>Gouttefangeas, Cécile</creator><creator>Schuhmacher, Juliane</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0553-3474</orcidid><orcidid>https://orcid.org/0000-0002-6410-2378</orcidid><orcidid>https://orcid.org/0000-0001-7928-7312</orcidid><orcidid>https://orcid.org/0000-0001-5312-2755</orcidid></search><sort><creationdate>20210203</creationdate><title>CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy</title><author>Richardson, Jennifer R ; Schöllhorn, Anna ; Gouttefangeas, Cécile ; Schuhmacher, Juliane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-2a4a2e9c1092897caac40c1337d501bfea11d8c0070b90ebdc3113e10998f7653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Antitumor activity</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Cell activation</topic><topic>Chemokines</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Growth factors</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Major histocompatibility complex</topic><topic>Pathogens</topic><topic>Peptides</topic><topic>Review</topic><topic>T cell receptors</topic><topic>Tumor cells</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richardson, Jennifer R</creatorcontrib><creatorcontrib>Schöllhorn, Anna</creatorcontrib><creatorcontrib>Gouttefangeas, Cécile</creatorcontrib><creatorcontrib>Schuhmacher, Juliane</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richardson, Jennifer R</au><au>Schöllhorn, Anna</au><au>Gouttefangeas, Cécile</au><au>Schuhmacher, Juliane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-02-03</date><risdate>2021</risdate><volume>13</volume><issue>4</issue><spage>596</spage><pages>596-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33546283</pmid><doi>10.3390/cancers13040596</doi><orcidid>https://orcid.org/0000-0003-0553-3474</orcidid><orcidid>https://orcid.org/0000-0002-6410-2378</orcidid><orcidid>https://orcid.org/0000-0001-7928-7312</orcidid><orcidid>https://orcid.org/0000-0001-5312-2755</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-02, Vol.13 (4), p.596 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7913359 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Antigens Antitumor activity Cancer Cancer immunotherapy CD4 antigen CD8 antigen Cell activation Chemokines Cytokines Cytotoxicity Growth factors Immunotherapy Ligands Lymphocytes Lymphocytes T Macrophages Major histocompatibility complex Pathogens Peptides Review T cell receptors Tumor cells Tumor necrosis factor-TNF |
| title | CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T20%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD4+%20T%20Cells:%20Multitasking%20Cells%20in%20the%20Duty%20of%20Cancer%20Immunotherapy&rft.jtitle=Cancers&rft.au=Richardson,%20Jennifer%20R&rft.date=2021-02-03&rft.volume=13&rft.issue=4&rft.spage=596&rft.pages=596-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13040596&rft_dat=%3Cproquest_pubme%3E2487224245%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487224245&rft_id=info:pmid/33546283&rfr_iscdi=true |